VYNE Therapeutics Inc. reported a third‑quarter 2025 net loss of $7.3 million, a 40% reduction from the $12.2 million loss in the same period a year earlier, and revenue of $0.2 million, up 100% from $0.1 million in Q3 2024. The loss per share of $‑0.17 beat consensus estimates of $‑0.19 by $0.02, a 10.5% improvement that reflects tighter cost control and a lower mix of high‑expense research projects.
Cash, cash equivalents and marketable securities totaled $32.7 million as of September 30, 2025, giving the company a runway that extends into the first half of 2027. The extended runway is the result of a focused cost‑reduction program that cut R&D spending on repibresib and VYN202 by $1.2 million and reduced general and administrative expenses by $0.8 million, largely through lower employee‑related and consulting fees.
The company also announced the initiation of a repeat 12‑week non‑clinical toxicology study in dogs for its oral BET inhibitor VYN202. The study is intended to address a partial FDA hold on male subjects in the Phase 1b trial, a regulatory hurdle that has delayed enrollment. In addition, VYNE’s board is conducting a strategic review to evaluate financing, partnership or acquisition opportunities, signaling a proactive approach to maximizing shareholder value.
Comparing to the immediately preceding quarter, Q2 2025 saw a net loss of $5.8 million and revenue of $0.1 million. The current quarter’s loss is 25% lower and revenue is 100% higher, indicating a clear acceleration in the company’s financial trajectory despite the ongoing clinical‑development focus.
CEO David Domzalski said, “We have made considerable progress in evaluating a number of potential value‑creating opportunities as part of our strategic review process, and we look forward to providing an update on these efforts as soon as possible. In parallel, we initiated a repeat 12‑week, non‑clinical toxicology study in dogs for VYN202. We believe a successful outcome from this study will enable us to remove the partial hold for testing VYN202 in male clinical subjects across a range of potential immuno‑inflammatory diseases.”
The extended cash runway and the progress on the VYN202 toxicology study provide a tailwind for VYNE, while the partial FDA hold and the termination of the repibresib gel Phase 2b extension phase remain headwinds. The company’s focus on cost discipline, strategic review, and pipeline advancement positions it to navigate these challenges and pursue opportunities that could accelerate its path to commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.